|
FDA to Remove APIs from listOn August 28, 2018, the FDA announced via federal register notice, their intent to remove three active ingredients, Bumetanide, Nicardipine HCI, and Vasopressin, from the list of Bulk Drug Substances that can be used to compound drug products under section 503B of the FD&C act. The reasons stated for the removal were,… |
CQI Partner Program – Newly Revised and ExpandedDYNALABS is excited to announce the launch of our revised and expanded CQI Partner Program. This innovative and comprehensive new program is geared at helping our clients foster a culture of continuous quality improvement, by establishing the systems necessary to meet quality and regulatory requirements. The program aims to achieve these goals by approaching them from both the side of DYNALABS and our clients. Every client that does business with DYNALABS has access to the products and services associated with this program, which include Production Systems, Improvement Systems, Laboratory Services, Data Analytics, and Consulting Services. We will be highlighting different aspects of the CQI Partner Program in future issues of The Pharma Report, so stay tuned! For more information, please contact us at sales@dynalabs.us, or click the URL below to learn more about the program. |
|
|
|